156 related articles for article (PubMed ID: 20640575)
1. Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha.
Juengel E; Bhasin M; Libermann T; Barth S; Michaelis M; Cinatl J; Jones J; Hudak L; Jonas D; Blaheta RA
World J Urol; 2011 Dec; 29(6):779-86. PubMed ID: 20640575
[TBL] [Abstract][Full Text] [Related]
2. Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.
Juengel E; Makarević J; Tsaur I; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
PLoS One; 2013; 8(1):e53100. PubMed ID: 23372654
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.
Jones J; Juengel E; Mickuckyte A; Hudak L; Wedel S; Jonas D; Blaheta RA
J Cell Mol Med; 2009 Aug; 13(8B):2376-2385. PubMed ID: 18657224
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.
Jones J; Juengel E; Mickuckyte A; Hudak L; Wedel S; Jonas D; Hintereder G; Blaheta RA
J Cell Mol Med; 2009 Aug; 13(8B):2342-2352. PubMed ID: 19067765
[TBL] [Abstract][Full Text] [Related]
5. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
Iwahashi S; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Mori H; Hanaoka J; Sugimoto K; Saito Y
Int J Clin Oncol; 2011 Dec; 16(6):671-8. PubMed ID: 21556798
[TBL] [Abstract][Full Text] [Related]
7. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
9. Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Xi W; Chen X; Sun J; Wang W; Huo Y; Zheng G; Wu J; Li Y; Yang A; Wang T
Med Sci Monit; 2018 Feb; 24():1034-1043. PubMed ID: 29457966
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
Juengel E; Engler J; Mickuckyte A; Jones J; Hudak L; Jonas D; Blaheta RA
BJU Int; 2010 Feb; 105(4):549-57. PubMed ID: 19594733
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.
Wei M; Mao S; Lu G; Li L; Lan X; Huang Z; Chen Y; Zhao M; Zhao Y; Xia Q
BMC Cancer; 2018 Apr; 18(1):434. PubMed ID: 29665787
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional program associated with IFN-alpha response of renal cell carcinoma.
Banerjee D; Chadalavada RS; Bourdon V; Korkola JE; Motzer RJ; Chaganti RS
J Interferon Cytokine Res; 2006 Mar; 26(3):156-70. PubMed ID: 16542138
[TBL] [Abstract][Full Text] [Related]
13. Low expression of microphthalmia-associated transcription factor, a potential molecular target for interferon-alpha susceptibility, is associated with metastasis in renal cell carcinoma.
Shimazui T; Kojima T; Yoshikawa K; Ami Y; Oikawa T; Uchida K; Akaza H
Cancer Sci; 2009 Sep; 100(9):1714-8. PubMed ID: 19496784
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Effects of Valproic Acid Treatment on Cell Survival and Epithelial-Mesenchymal Transition-Related Features of Human Gastric Cancer Cells.
Jahani M; Khanahmad H; Nikpour P
J Gastrointest Cancer; 2021 Jun; 52(2):676-681. PubMed ID: 32621111
[TBL] [Abstract][Full Text] [Related]
15. Effects of histone deacetylase inhibitors on regenerative cell responses in human dental pulp cells.
Luo Z; Wang Z; He X; Liu N; Liu B; Sun L; Wang J; Ma F; Duncan H; He W; Cooper P
Int Endod J; 2018 Jul; 51(7):767-778. PubMed ID: 28375564
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid.
Oertl A; Relja B; Makarevic J; Weich E; Höfler S; Jones J; Jonas D; Bratzke H; Baer PC; Blaheta RA
Int J Mol Med; 2006 Aug; 18(2):347-54. PubMed ID: 16820945
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Wang XF; Qian DZ; Ren M; Kato Y; Wei Y; Zhang L; Fansler Z; Clark D; Nakanishi O; Pili R
Clin Cancer Res; 2005 May; 11(9):3535-42. PubMed ID: 15867257
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis.
Iwahashi S; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Mori H; Hanaoka J; Saito Y
Oncol Rep; 2011 Nov; 26(5):1057-62. PubMed ID: 21805043
[TBL] [Abstract][Full Text] [Related]
19. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
